Denkert C, Rachakonda S, Karn T, et al. Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping (PenelopeB) (PMID: 39933898). Cancer Cell. 2025.
Category: Publication
Study protocol of the METAPANC trial – intensified treatment in patients with local operable but oligometastatic pancreatic cancer – multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial
Ghadimi M, Pelzer U, Besselink MG, et al. Study protocol of the METAPANC trial – intensified treatment in patients with local operable but oligometastatic pancreatic cancer – multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial (PMID: 39915735). BMC Cancer. 2025.
Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response
Hofer S, Frasch L, Brajkovic S, et al. Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response (PMID: 39838187). Mol Syst Biol. 2025.
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence
Keyl J, Keyl P, Montavon G, et al. Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence (PMID: 39885364). Nat Cancer. 2025.
Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA
Metzenmacher M, Zaun G, Trajkovic-Arsic M, et al. Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA (PMID: 39478658). Mol Oncol. 2025.
Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility
Schwerd-Kleine P, Wurth R, Cheytan T, et al. Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility (PMID: 40022208). Int J Cancer. 2025.
Structural variant and nucleosome occupancy dynamics postchemotherapy in a HER2+ breast cancer organoid model
Starostecka M, Jeong H, Hasenfeld P, et al. Structural variant and nucleosome occupancy dynamics postchemotherapy in a HER2+ breast cancer organoid model (PMID: 39993200). Proc Natl Acad Sci U S A. 2025.
KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening
Tapia Contreras C, Falke JD, Seifert DM, et al. KRAS(G) (12C)-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening (PMID: 39253995). Mol Oncol. 2025.
Characterization of single neurons reprogrammed by pancreatic cancer
Thiel V, Renders S, Panten J, et al. Characterization of single neurons reprogrammed by pancreatic cancer (PMID: 39961335). Nature. 2025.
Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling
Wurth R, Donato E, Michel LL, et al. Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling (PMID: 39753722). Nat Cancer. 2025.
